File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies

TitleComparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies
Authors
KeywordsNasopharyngeal Carcinoma
Induction chemotherapy
Survival outcome
Pooled analysis
Issue Date2021
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology
Citation
Oral Oncology, 2021, v. 114, p. article no. 105158 How to Cite?
AbstractPurpose: We compared, in this pooled analysis, the differences in efficacy and safety between three induction chemotherapy regimens including gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) in patients recruited into our two prospective studies for previously untreated locoregionally advanced nasopharyngeal carcinoma (NPC). Methods: GP, PF or PX followed by radical concurrent chemoradiotherapy was given to patients with previously untreated locoregionally advanced (stage III to IVA) NPC prospectively recruited into our two prospective studies. The study endpoints included progression-free survival (PFS) and overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and major acute and late treatment-related toxicities (grade ≥ 3). Results: From 2006 to 2016, 278 patients were enrolled (84, 94 and 100 patients in GP, PF and PX group respectively). After a median follow-up of 80 months, the 3-year PFS, OS, LRFS, DMFS and CSS of the whole population were 78.7%, 88.1%, 84.9%, 80.9% and 89.8%, respectively. There were no significant differences in prespecified survival endpoints among GP, PF and PX in both stage III and stage IVA patients. GP had lower incidences of severe (grade ≥ 3) anemia and diarrhea in stage III patients, as well as severe anemia, dehydration, renal impairment and vomiting in stage IVA patients. The incidences of grade ≥ 3 late toxicities were similar among these 3 induction regimens. Conclusion: GP had similar efficacy and potentially fewer treatment-related complications compared with PF and PX as induction chemotherapy for previously untreated locoregionally advanced NPC.
Persistent Identifierhttp://hdl.handle.net/10722/300663
ISSN
2020 Impact Factor: 5.337
2020 SCImago Journal Rankings: 1.623
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCHAN, SK-
dc.contributor.authorChan, SY-
dc.contributor.authorTong, CC-
dc.contributor.authorLam, KO-
dc.contributor.authorKwong, DLW-
dc.contributor.authorLeung, TW-
dc.contributor.authorLuk, MY-
dc.contributor.authorLee, AWM-
dc.contributor.authorChoi, HCW-
dc.contributor.authorLee, VHF-
dc.date.accessioned2021-06-18T14:55:13Z-
dc.date.available2021-06-18T14:55:13Z-
dc.date.issued2021-
dc.identifier.citationOral Oncology, 2021, v. 114, p. article no. 105158-
dc.identifier.issn1368-8375-
dc.identifier.urihttp://hdl.handle.net/10722/300663-
dc.description.abstractPurpose: We compared, in this pooled analysis, the differences in efficacy and safety between three induction chemotherapy regimens including gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) in patients recruited into our two prospective studies for previously untreated locoregionally advanced nasopharyngeal carcinoma (NPC). Methods: GP, PF or PX followed by radical concurrent chemoradiotherapy was given to patients with previously untreated locoregionally advanced (stage III to IVA) NPC prospectively recruited into our two prospective studies. The study endpoints included progression-free survival (PFS) and overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and major acute and late treatment-related toxicities (grade ≥ 3). Results: From 2006 to 2016, 278 patients were enrolled (84, 94 and 100 patients in GP, PF and PX group respectively). After a median follow-up of 80 months, the 3-year PFS, OS, LRFS, DMFS and CSS of the whole population were 78.7%, 88.1%, 84.9%, 80.9% and 89.8%, respectively. There were no significant differences in prespecified survival endpoints among GP, PF and PX in both stage III and stage IVA patients. GP had lower incidences of severe (grade ≥ 3) anemia and diarrhea in stage III patients, as well as severe anemia, dehydration, renal impairment and vomiting in stage IVA patients. The incidences of grade ≥ 3 late toxicities were similar among these 3 induction regimens. Conclusion: GP had similar efficacy and potentially fewer treatment-related complications compared with PF and PX as induction chemotherapy for previously untreated locoregionally advanced NPC.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology-
dc.relation.ispartofOral Oncology-
dc.subjectNasopharyngeal Carcinoma-
dc.subjectInduction chemotherapy-
dc.subjectSurvival outcome-
dc.subjectPooled analysis-
dc.titleComparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies-
dc.typeArticle-
dc.identifier.emailTong, CC: tccz01@HKUCC-COM.hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hk-
dc.identifier.emailLuk, MY: myluk@hkucc.hku.hk-
dc.identifier.emailLee, AWM: awmlee@hkucc.hku.hk-
dc.identifier.emailChoi, HCW: hcchoi@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityKwong, DLW=rp00414-
dc.identifier.authorityLee, AWM=rp02056-
dc.identifier.authorityChoi, HCW=rp02815-
dc.identifier.authorityLee, VHF=rp00264-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.oraloncology.2020.105158-
dc.identifier.pmid33508707-
dc.identifier.scopuseid_2-s2.0-85099851176-
dc.identifier.hkuros322772-
dc.identifier.volume114-
dc.identifier.spagearticle no. 105158-
dc.identifier.epagearticle no. 105158-
dc.identifier.isiWOS:000624972300001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats